Reply to: "Improved basic performance of iTACT-HBcrAg assay" and "Using a commercial diagnostic assay requires compliance with the manufacturer's recommendations"
- PMID: 37392839
- DOI: 10.1016/j.jhep.2023.05.047
Reply to: "Improved basic performance of iTACT-HBcrAg assay" and "Using a commercial diagnostic assay requires compliance with the manufacturer's recommendations"
Comment on
-
Improved basic performance of iTACT-HBcrAg assay.J Hepatol. 2023 Sep;79(3):e133-e134. doi: 10.1016/j.jhep.2023.03.008. Epub 2023 Mar 24. J Hepatol. 2023. PMID: 36965779 No abstract available.
-
Using a commercial diagnostic assay requires compliance with the manufacturer's recommendations.J Hepatol. 2023 Sep;79(3):e134-e135. doi: 10.1016/j.jhep.2023.04.009. Epub 2023 Apr 20. J Hepatol. 2023. PMID: 37086922 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
